How lenalidomide is changing the treatment of patients with multiple myeloma.

How lenalidomide is changing the treatment of patients with multiple myeloma.

Item
http://www.wikidata.org/entity/Q38118427
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaImmunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myelomaTherapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents
P2860

How lenalidomide is changing the treatment of patients with multiple myeloma.

Item
http://www.wikidata.org/entity/Q38118427
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
type
label
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
prefLabel
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
P1433
P1476
P2093
P304
P31
P356
P478
P50
P577
P698
P356
P1433
P1476
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
P2093
P304
P31
P356
10.1016/J.CRITREVONC.2013.05.013
P478
P50
P577
P698